Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck CancerBusiness Wire • 06/24/24
Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024Business Wire • 05/23/24
Merck KGaA's experimental MS drug fails in late stage trials sending shares tumblingProactive Investors • 12/06/23
Exscientia's stock rockets toward a record gain after AI-driven drug discovery collaboration with Germany's Merck KGaAMarket Watch • 09/20/23
Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug DiscoveryBusiness Wire • 09/20/23
Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)Business Wire • 03/27/23
MERCK Kommanditgesellschaft auf Aktien (MKGAF) Q4 2022 Results - Earnings Call TranscriptSeeking Alpha • 03/02/23